Clinical Trial Search

Primary: Change in Body Weight (%) - Semaglutide 2.4 mg Versus Placebo — -9.9; -3.3; -10.7; -3.1 Percentage point of body weight — p=<0.0001

Primary: Specificity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer…

Primary: Change From Baseline in the Mean Number of Total Migraine Days Per Month in the Last 4 Weeks of the DBT Phase — -4.3; -3.5 Total Migraine Days per Month — p=0.0099

Primary: Number of Participants With an Adverse Event (AE) — 12; 10; 27; 24 Participants

Primary: Percentage of Participants Demonstrating at Least a 50% Reduction on Montgomery-Asberg Depression Rating Scale Scores — 0; 2; 8; 6 Participants

Primary: Disease-free Survival — 73.4; 76.3 percentage of participants — p=0.12

Primary: Ratio of Annualized Bleeding Rate (ABR) for Spontaneous Bleeding Episodes (BEs) (On-study ABR / Historical ABR) Assessed by Investigator During Prophylactic Treatment…

Primary: The Proportions of Participants Who Experienced Complete Response of the Study Chalazion by Day 15 ± 1 — 28; 32 Participants — p=0.579

Primary: Number of Subjects in the Safety Analysis Set With at Least 1 Treatment-emergent Adverse Event (TEAE) — 84; 14; 10; 1 Participants

Primary: Percentage of Participants With Adverse Events of Primary Interest (AEPIs) — 23.1; 51.4 Percentage of Participants

Primary: Change From Baseline in Body Weight — -1.67; -1.36 kg

Primary: Objective Response Rate (ORR) - Part 1 — 0; 0; 6; 3 Participants

Primary: The Proportion of Subjects Ages 4-17 Who Tolerated a Single Highest Dose of at Least 1000 mg in the Exit Oral Food Challenge. — 77; 1 Participants — p=<0.0001

Primary: Lung Cancer Recurrence or Mortality - 2 Years — 80; 85 Participants — p=0.94

Primary: Progression Free Survival (PFS) — 4.14; 3.15 Months — p=0.0184